Document Detail

Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
MedLine Citation:
PMID:  15134826     Owner:  NLM     Status:  MEDLINE    
CONCLUSIONS: DRSP, by its anti-MCR effect and its potential to slightly decrease body weight and blood pressure, shares many pharmacodynamic properties with progesterone, and it is a candidate for reducing cardiovascular morbidity in women using OCs or postmenopausal hormone treatment.
Wolfgang Oelkers
Related Documents :
1530806 - Is there a relationship between exercise systolic blood pressure response and left vent...
659046 - Glucose tolerance and blood pressure in two population samples: their relation to diabe...
10920346 - Report of the national high blood pressure education program working group on high bloo...
15516396 - Vascular reactivity in preeclampsia assessed noninvasively using maternal brachial arte...
23550916 - Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol...
23479456 - Prolonged hypotensive and bradycardic effects of passive mandibular extension: evidence...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Molecular and cellular endocrinology     Volume:  217     ISSN:  0303-7207     ISO Abbreviation:  Mol. Cell. Endocrinol.     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-05-11     Completed Date:  2005-02-08     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  7500844     Medline TA:  Mol Cell Endocrinol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  255-61     Citation Subset:  IM    
Department of Internal Medicine, Division of Endocrinology, Diabetes and Nutrition, Klinikum Benjamin Franklin, Freie Universität Berlin, Hindenburgdamm 30, 12200 Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androstenes / administration & dosage*
Blood Pressure / drug effects*
Cardiovascular System
Clinical Trials as Topic
Contraceptives, Oral / administration & dosage
Drug Interactions*
Drug Therapy, Combination
Estrogen Replacement Therapy / adverse effects
Middle Aged
Mineralocorticoid Receptor Antagonists* / administration & dosage*
Progesterone / pharmacology*
Weight Gain / drug effects
Reg. No./Substance:
0/Androstenes; 0/Contraceptives, Oral; 0/Mineralocorticoid Receptor Antagonists; 57-83-0/Progesterone; N295J34A25/drospirenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and ...
Next Document:  Aldosterone, mineralocorticoid receptors and vascular inflammation.